Microchip Biotech announced on October 16 that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the clinical trial application for injectable NW001 developed by the company in cooperation with Chengdu Microchip Xinyu Biotechnology Co., Ltd. for the treatment of advanced malignant tumors was approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.